Repeated intravitreal injections of antivascular endothelial growth factors and risk of intraocular pressure medication use.

ABSTRACT:

Purpose

To determine the risk of initiating ocular hypertension and glaucoma treatment with repeated injections of antivascular endothelial growth factors (anti-VEGF).

Methods

A unique, retrospective cohort study was performed using a large national US medical claim database. The study population included patients who had 1 or more injections of an anti-VEGF agent. Exclusion occurred for any previous glaucoma, glaucoma suspect, glaucoma-related procedure, an ocular steroid injection, or not seeing an eye care provider at least once in each year of follow-up. Cohorts were divided into quartiles based on the number of injections performed over the follow-up period. Patients were observed for 2 and 3 years. The main outcome measure was defined as any new prescription for an ocu

SUBMITTER: Cui QN 

PROVIDER: S-EPMC6698200 | biostudies-literature | 2019 Sep

REPOSITORIES: biostudies-literature